TransEnterix Announces Sinai Health System in Chicago to Initiate Program with the Senhance Surgical System
21 Mayo 2020 - 5:55AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that the Sinai Health System in Chicago has entered into an
agreement to lease and utilize a Senhance® Surgical System, which
would be the first facility in Chicago to move in this
direction.
“Our team is excited that Sinai Health System has chosen to add
the Senhance Digital Laparoscopy Platform to its minimally invasive
surgery program,” said Anthony Fernando, president and chief
executive officer at TransEnterix. “In the midst of the challenging
times posed by COVID-19, hospitals are looking to the future and
continue to seek more advanced and cost-effective technologies to
treat their patients undergoing surgery. We are thrilled to partner
with the excellent surgical team at Sinai Health System.”
The Senhance System is the first new abdominal robotic surgery
platform to receive FDA clearance since 2000. It is the first and
only digital laparoscopic surgical platform designed to maintain
laparoscopic MIS standards while providing digital benefits such as
haptic feedback, robotic precision, comfortable ergonomics,
advanced instrumentation including, 3 mm microlaparoscopic
instruments, eye sensing camera control and reusable standard
instruments to help maintain per-procedure costs similar to
traditional laparoscopy. In March 2020, TransEnterix received FDA
clearance for the first machine vision system in robotic surgery
which powers the new Intelligent Surgical Unit capability of
Senhance.
“We chose the Senhance Surgical System because it offers unique
capabilities in adding robotics to our surgical program,” said Dr.
Carlos Sandoval-Herrera FACOG, Director of Gynecology and Chief of
the Division of Minimally Invasive Gynecologic Surgery at Sinai
Health System. “This technology offers the opportunity to use
instruments as small as 3mm with robotic assistance, which can help
offer many patients virtually scarless surgery. The advances being
made with augmented intelligence utilizing this system are truly
the future in using digital information to better guide and control
surgery.”
“As a health system, we seek to offer the best possible care
utilizing the latest technology to all the patients we serve in our
community, and we are proud to be the first hospital in Chicago to
launch the Senhance surgical program,“ said Dr. Airica Steed,
System Chief Operating Officer and Executive Vice President of
Sinai Health System. “We are pleased to build upon our excellent
outcomes at the Center of Excellence in Minimally Invasive
Gynecological Surgery at Sinai Health System and utilize robotic
surgery with Senhance to offer patients fast recovery with minimal
pain and scarring.”
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
market development activities for, and increasing utilization of,
its Senhance Surgical System, which digitizes laparoscopic
minimally invasive surgery. The system allows for robotic
precision, haptic feedback, surgeon camera control via eye sensing
and improved ergonomics while offering responsible economics. The
Senhance Surgical System is available for sale in the US, the EU,
Japan and select other countries. For more information, visit
www.transenterix.com.
About Sinai Health System
Sinai Health System, a Chicago-based private, not-for-profit
organization, is comprised of seven member organizations: Mount
Sinai Hospital, Holy Cross Hospital, Sinai Children’s Hospital,
Schwab Rehabilitation Hospital, Sinai Medical Group, Sinai
Community Institute and Sinai Urban Health Institute. The system
has over 800 physicians on its hospital medical staffs, 654
licensed beds, 100,000+ annual emergency department patient visits
and eight physician residency training programs. For more
information, visit www.sinai.org.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Sinai Health System in Chicago initiating a program
with the Senhance System. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether the Senhance System will provide advanced and
cost-effective technologies for the patients undergoing surgery;
and whether the advances being made with augmented intelligence
utilizing the Senhance System will be the future in using digital
information to better guide and control surgery. For a discussion
of the risks and uncertainties associated with TransEnterix's
business, please review our filings with the Securities and
Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the SEC on March
16, 2020 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200521005083/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com
or
Media Contact: Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024